Open AccessThis article is
- freely available
Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer
Discipline of Obstetrics and Gynaecology, School of Paediatrics and Reproductive Health, Research Centre for Reproductive Health, Robinson Institute, University of Adelaide, Adelaide 5005, Australia
Genetics and Molecular Pathology, SA Pathology, Women's and Children's Hospital, Adelaide 5006, Australia
Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide 5000, Australia
* Author to whom correspondence should be addressed.
Received: 1 February 2013; in revised form: 6 March 2013 / Accepted: 7 March 2013 / Published: 10 April 2013
Abstract: Ovarian cancer remains the most lethal gynaecological cancer. A better understanding of the molecular pathogenesis of ovarian cancer is of critical importance to develop early detection tests and identify new therapeutic targets that would increase survival. Cancer cells depend on de novo lipid synthesis for the generation of fatty acids to meet the energy requirements for increased tumour growth. There is increasing evidence that lipid metabolism is deregulated in cancers, including ovarian cancer. The increased expression and activity of lipogenic enzymes is largely responsible for increased lipid synthesis, which is regulated by metabolic and oncogenic signalling pathways. This article reviews the latest knowledge on lipid metabolism and the alterations in the expression of lipogenic enzymes and downstream signalling pathways in ovarian cancer. Current developments for exploiting lipids as biomarkers for the detection of early stage ovarian cancer and therapeutic targets are discussed. Current research targeting lipogenic enzymes and lipids to increase the cytotoxicity of chemotherapy drugs is also highlighted.
Keywords: ovarian cancer; lipid synthesis; signalling pathways; biomarkers; therapeutic targets
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Pyragius, C.E.; Fuller, M.; Ricciardelli, C.; Oehler, M.K. Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer. Int. J. Mol. Sci. 2013, 14, 7742-7756.
Pyragius CE, Fuller M, Ricciardelli C, Oehler MK. Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer. International Journal of Molecular Sciences. 2013; 14(4):7742-7756.
Pyragius, Carmen E.; Fuller, Maria; Ricciardelli, Carmela; Oehler, Martin K. 2013. "Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer." Int. J. Mol. Sci. 14, no. 4: 7742-7756.